The ability of hyperantigenic preparations of synthetically produced Escherichia coli heat-stable toxin (ST) to provide an immunogenically more potent vaccine when cross-linked by the glutaraldehyde reaction to the heat-labile toxin B subunit was assesed. Three synthetic ST preparations were evaluated: ST(S) had the same antigenicity and toxicity (secretory potency in the suckling mouse assay) as native ST, ST 1056 had 3.5-fold more antigenicity and 1% toxicity, and ST(C) had 15-fold greater antigenicity and 31% toxicity. Vaccines that contained equal antigenic proportions of ST and B subunit, as determined by enzyme-linked immunosorbent assays, consisted by weight of 52% ST(S), 25% ST 1056, and 9% ST(C). The initially lower toxicity and smaller proportions by weight of hyperantigenic ST preparations yielded vaccines that had nearly 10-fold less residual ST toxicity than the ST(S) vaccine. Immunization of rats with graded dosages of vaccines containing 9% ST(C) and 51% ST(S) by weight, but equal amounts of ST(S) antigenicity, raised to the same degree dose-dependent increases in mucosal immunoglobulin A antitoxin titers to ST(S) which correlated with the amount of protection against challenge with a viable LT-/ST' strain. These observations indicate that hyperantigenic synthetic ST preparations provide immunologically more potent vaccines than those obtained with the previously used synthetic ST(S) preparation, which has the same biological properties as native ST.
One approach currently being considered for its potential to provide immunological protection against diarrheal disease caused by enterotoxigenic strains of Escherichia coli (ETEC) is immunization with cross-linked toxoid forms of the heat-stable (ST) and heat-labile (LT) toxins that are produced by such strains. In contrast to the multiplicity, antigenic diversity, and high prevalence of unidentifiable forms of specific pilus antigens responsible for mucosal adherence among human ETEC strains (9, 28, 38) , both enterotoxins have been purified to homogeneity, and their properties have been well characterized. Although some degree of structural and immunological variation exists between toxins produced by human versus animal ETEC strains (1, 6, 11, 14) , both LT (or its nontoxic B subunit) and ST from either source have sufficient immunological homology so that immunization of experimental animals with them provides uniform active or passive protection against challenge with toxins produced by heterologous strains or with viable ETEC strains regardless of their source, somatic serotype, or pilus antigens (17, 21, 33) . LT and ST are antigenically distinct, however, so that immunization with either toxin form provides protection only against those ETEC strains which produce the homologous toxin, either singly or together or with the heterologous toxin (16, 18, 21) . This has been resolved by cross-linking the haptenic ST toxin to LT, thereby creating a vaccine that is immunogenic for both toxin forms (19) .
We have recently described the properties of a vaccine made by cross-linking ST to the B subunit of LT toxin (20) . The synthetically produced ST preparation used, ST(S), consists of the same amino acid sequence and has the same scretory potency and antigenic properties as native ST (22) . Based on our finding that the immunogenicities of ST(S) and the LT B subunit are the same when tested by immunization with graded dosages of each in experimental animals, the cross-linked vaccine is prepared to contain equal antigenic proportions of each toxin component (21) . The B subunit is nontoxic, the residual toxicity of the ST component is markedly reduced by the cross-linking reaction, and the vaccine has proven to be innocuous when given parenterally and/or perorally (p.o.) to various animal species, including dogs, rabbits, rats, guinea pigs, and mice (23; F. A. Klipstein, and R. F. Engert, unpublished data). When given by p.o. immunization to rats or rabbits, the vaccine raises dosedependent increases in specific immunoglobulin A (IgA) antitoxin titers to each toxin component in intestinal mucosal washings which correlate with the degree of protection against active challenge in ligated ileal loops with either the ST or LT toxin or with viable bacteria which produce them, either singly or together (19, 21, 23) .
In the present study, we determined whether a vaccine that is immunogenically more potent but has even less residual ST toxicity could be obtained by substituting other synthetically produced ST preparations whose stereochemistry was modified to yield toxins that have greater antigenicity but less toxicity (i.e., secretory activity) than ST(S). The composition, antigenicity, and residual ST toxicity of vaccines made by cross-linking two such hyperantigenic synthetic ST preparations to human LT B subunit were compared with the one previously tested which used ST(S). The increased immunogenicity of one of the hyperantigenic ST preparations was confirmed by determining the mucosal IgA antitoxin response and degree of protection in rats that were given p.o. immunization with graded dosages of vaccines containing either ST(S) or the hyperantigenic ST preparation. (13, 25) . Conjugation conditions. The three synthetic ST preparations were cross-linked to B subunit by mixing various initial molar ratios of these toxins in the presence of Sigma grade I glutaraldehyde (GA) (Sigma Chemical Co., St. Louis, Mo.). The ratio of GA to total protein of the toxin mixtures was varied in each reaction so that the GA to B subunit molar ratio was kept constant at 700:1. This concentration of GA was used because it was found to provide effective crosslinking without attenuation of B subunit antigenicity (F. A. Klipstein and R. F. Engert, unpublished observations). After a 2-h reaction at room temperature, the conjugates were rapidly chilled, exhaustively dialyzed for 48 h against TEAN buffer (Tris, EDTA, sodium azide, NaCI) at 4°C, and then processed as described previously (20) .
The antigenicities of the toxin materials, either alone or in conjugated form, were determined by enzyme-linked immunosorbent assay (ELISA) as described previously (20, 22) . Antitoxin response. Mucosal IgA antitoxin titers to ST(S) and the B subunit were determined by ELISA as described previously (19, 21) . Antitoxin 
RESULTS
Properties of the synthetic ST preparation. The antigenicity of ST 1056 was 3.5-fold greater and that of ST(C) was 15-fold greater than the antigenicity of ST(S) as determined by ELISA using hyperimmune antisera to ST(S) (Fig. 1) . Val (Fig. 2) by the carbodiimide reaction as described previously (21) 
DISCUSSION
ST has been purified from human (35, 37) , porcine (3, 24) , and bovine (34) ETEC strains, and the amino acid sequence of the human (1, 4, 32, 36) and porcine (24, 25) toxins has been determined. The toxins consist of 18 or 19 amino acids, although the active site is confined to the C-terminal 14 amino acid residues. One-third of the molecule consists of six cysteine residues which are joined together by disulfide bridges. Although some variation has been noted among different preparations, principally in the presence of tyrosine versus asparagine at the C-terminal 4 and 8 positions, the basic structure of human and porcine ST is remarkably similar. ST preparations based on this structure have now been produced synthetically by several laboratories. The ST(S) preparation which we have used previously (20, 21, 23) is based on the 18-amino acid sequence described by Chan and Giannella for human ST (4) ; it is identical in terms of biological and antigenic properties to native ST (22) . Ikemura et al have used solution methods to produce a 19-amino acid peptide, containing tyrosine rather than asparagine at the C-terminal 4 and 8 positions, which also has the same secretory potency as native human ST (15) . A shorter peptide, consisting of 14 terminal amino acid residues, has been reported by Aimoto et al. to be two to five times more potent than native ST (2). Our observations in the present study indicate that both the biological and antigenic properties of synthetically produced ST can be modified by altering the stereochemistry of the molecule by means of rearrangement of the disulfide bridges.
ST toxins produced by different ETEC strains from human and animal sources also appear to be closely related immunologically. Hyperimmune antisera raised to purified human or porcine ST cross-react in radioimmunoassays with ST produced by human, porcine, and bovine strains (10, 12) . Immunization of rats with ST(S) provides an equal degree of protection against active challenge with heterologous somatic serotypes of ETEC strains of either human or porcine origin (21) . Our present studies were not dictated, therefore, by any need to extend the spectrum of protection afforded by immunization with synthetic human ST, but rather were concerned with determining whether an immunologically more potent vaccine could be developed by the use of hyperantigenic ST preparations.
Each of the modified synthetic preparations evaluated in vaccine form was selected because of its specific properties: ST(C) had markedly increased antigenicity but only moderately reduced toxicity (secretory potency), whereas ST 1056 had markedly decreased toxicity but only moderately increased antigenicity. We found that the potential advantage gained by the initial low toxicity of ST 1056 was largely negated by the fact that the degree of attenuation of toxicity afforded by the cross-linking reaction was proportional to the intial toxicity of ST preparations, so that the toxicity of ST(C) was reduced nearly six times more than that of ST 1056. As a result, the more antigenic ST(C) preparation yielded a vaccine that was antigenically more potent but no more toxic than that derived from ST 1056. The ST(C)-B subunit vaccine had nearly twice the antigenic potency for both toxin components and one-tenth the residual ST toxicity of the previously used ST(S)-B subunit vaccine. Furthermore, the amount of ST(C) necessary to make vaccine containing 1,000 AU of each toxin component was a quarter less than that needed using ST(S).
Central to the importance of the hyperantigenic ST preparations as prospective vaccine components was the demonstration that their hyperantigenicity, as determined by ELISA, correlated with greater immunogenicity, as determined by their effectiveness in arousing an antitoxin response and providing protection against challenge in immunized experimental animals at lower dosages than ST(S). Since the antigenicity of ST in conjugated form is a function of the proportion by weight of ST in that conjugate, the initial antigenicity of the ST preparation, and the degree to which the antigenicity is compromised by the cross-linking reaction, the expression of the dosage of the conjugate oil a weight basis does not provide meaningful information unless its ST antigenicity is directly measured. When this is done and the amount of ST is expressed in AU, then immunization with ST(S), conjugated either to the B subunit or an immunologically nonspecific protein carrier, yields a dose-dependent response of mucosal antitoxin levels and degree of protection against active challenge (21) . Similarly, immunization with either the ST(S) or ST(C) vaccine in the present study raised an identical response when their dosages were expressed as AU based on ST(S) antigenicity. When, on the other hand, dosages were expressed on a weight basis, Two other modifications were incorporated into the present study which facilitated the production of a more efficiently produced vaccine. The first was that the B subunit was obtained directly from an E. coli K-12 strain that had been modified by recombinant techniques to produce only human B subunit (5), rather than by dissociation procedures from the LT holotoxin as we have done in the past. The second was that GA was substituted for carbodiimide as the cross-linking reagent. GA has a number of advantages. (i) At the proper concentration, it provides effective cross-linking of ST to the B subunit without affecting their antigenicities.
(ii) It yields more efficient coupling of ST to B subunit, so that vaccines containing equal antigenic proportions of ST and B subunit can be derived from lower initial molar ratios of ST to B subunit, thereby significantly reducing the amount of ST needed to make the vaccine (F. A. Klipstein and R. F. Engert, unpublished observations). (iii) Unlike carbodiimide, there is a considerable body of experience that attests to the safety of administering GA conjugates to humans (8, 26, 31) . GA toxoids lost favor a decade ago when immunization with GA-treated cholera toxoid provided disappointing results in humans (27, 30) ; however, methods such as ELISA were not then available to determine the actual antigenicity of these toxoids, so that immunization dosages were unknown in terms of the number of cholera AU given. When expressed in this manner in the present study, the dose-dependent responses to vaccines crosslinked using either GA or carbodiimide were identical.
